OUR PROGRAMS

The company’s pipeline spans key areas of high unmet need, including:

  • Metabolic dysfunction-associated steatohepatitis (MASH)
  • Alcohol use disorder (AUD)
  • Alcohol-associated liver disease (ALD)

By focusing on the underlying complexity of disease mechanisms, we aim to develop new therapies for patients. Altimmune’s lead candidate, pemvidutide*, is an investigational therapy designed to help address both the cause and the consequence of serious liver disease through direct liver effects via glucagon receptor activity and metabolic effects via GLP-1 activity.

VIEW PIPELINE

*Pemvidutide is investigational and has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. Safety and efficacy have not been established. There is no guarantee that it will successfully complete clinical development or receive regulatory approval.